JPH022861B2 - - Google Patents
Info
- Publication number
- JPH022861B2 JPH022861B2 JP56101665A JP10166581A JPH022861B2 JP H022861 B2 JPH022861 B2 JP H022861B2 JP 56101665 A JP56101665 A JP 56101665A JP 10166581 A JP10166581 A JP 10166581A JP H022861 B2 JPH022861 B2 JP H022861B2
- Authority
- JP
- Japan
- Prior art keywords
- improvement
- amantadine hydrochloride
- present
- patient
- hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 claims description 26
- 208000024891 symptom Diseases 0.000 claims description 17
- 206010019196 Head injury Diseases 0.000 claims description 12
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 10
- 208000006011 Stroke Diseases 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 8
- 230000003340 mental effect Effects 0.000 claims description 7
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 5
- 230000008450 motivation Effects 0.000 claims description 5
- 230000003933 intellectual function Effects 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 230000001771 impaired effect Effects 0.000 claims description 2
- 230000006872 improvement Effects 0.000 description 50
- WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 45
- 229960001280 amantadine hydrochloride Drugs 0.000 description 35
- 238000002360 preparation method Methods 0.000 description 22
- 201000010099 disease Diseases 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 238000009472 formulation Methods 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 229940079593 drug Drugs 0.000 description 17
- 239000003826 tablet Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 10
- 208000024827 Alzheimer disease Diseases 0.000 description 9
- 239000000825 pharmaceutical preparation Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 239000000829 suppository Substances 0.000 description 8
- 229940082537 amantadine hydrochloride 100 mg Drugs 0.000 description 7
- 239000007927 intramuscular injection Substances 0.000 description 7
- 238000010255 intramuscular injection Methods 0.000 description 7
- 206010010071 Coma Diseases 0.000 description 6
- 206010039966 Senile dementia Diseases 0.000 description 6
- 230000006399 behavior Effects 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 238000010253 intravenous injection Methods 0.000 description 6
- 239000007901 soft capsule Substances 0.000 description 6
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 5
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 208000001408 Carbon monoxide poisoning Diseases 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000015654 memory Effects 0.000 description 4
- 201000000980 schizophrenia Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010001605 Alcohol poisoning Diseases 0.000 description 3
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 3
- -1 Glycerin fatty acid ester Chemical class 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- PBKVEOSEPXMKDN-LZHUFOCISA-N chembl2311030 Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)CC)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 PBKVEOSEPXMKDN-LZHUFOCISA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 2
- 206010010075 Coma hepatic Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 208000007530 Essential hypertension Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010036631 Presenile dementia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 2
- 208000037132 Subdural Chronic Hematoma Diseases 0.000 description 2
- 208000002667 Subdural Hematoma Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000004503 fine granule Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 201000001059 hepatic coma Diseases 0.000 description 2
- 208000007386 hepatic encephalopathy Diseases 0.000 description 2
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003451 thiazide diuretic agent Substances 0.000 description 2
- 229940041597 tofranil Drugs 0.000 description 2
- FIVHOHCAXWQPGC-UHFFFAOYSA-N 2-[2-(4-chlorophenoxy)acetyl]oxyethyl-dimethylazanium;chloride Chemical compound Cl.CN(C)CCOC(=O)COC1=CC=C(Cl)C=C1 FIVHOHCAXWQPGC-UHFFFAOYSA-N 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 1
- 206010053942 Cerebral haematoma Diseases 0.000 description 1
- 208000022540 Consciousness disease Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000002230 Diabetic coma Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- IABBAGAOMDWOCW-UHFFFAOYSA-N Nicametate citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCN(CC)CCOC(=O)C1=CC=CN=C1 IABBAGAOMDWOCW-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000036002 Rash generalised Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 208000011318 facial edema Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000016657 midbrain disease Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10166581A JPS584718A (ja) | 1981-06-30 | 1981-06-30 | 新規適応症に用うる医薬製剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10166581A JPS584718A (ja) | 1981-06-30 | 1981-06-30 | 新規適応症に用うる医薬製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS584718A JPS584718A (ja) | 1983-01-11 |
| JPH022861B2 true JPH022861B2 (ru) | 1990-01-19 |
Family
ID=14306662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10166581A Granted JPS584718A (ja) | 1981-06-30 | 1981-06-30 | 新規適応症に用うる医薬製剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS584718A (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9382640B2 (en) | 2011-12-12 | 2016-07-05 | Shin-Etsu Quartz Products Co., Ltd. | Single crystal silicon pulling silica container and manufacturing method thereof |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6444702B1 (en) | 2000-02-22 | 2002-09-03 | Neuromolecular, Inc. | Aminoadamantane derivatives as therapeutic agents |
| JP2004515477A (ja) * | 2000-12-07 | 2004-05-27 | ニューロモレキュラー インコーポレイテッド | Ｎｍｄａレセプターアンタゴニストを用いて神経精神医学的障害を処置するための方法 |
| US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
| EP2243475B1 (en) | 2005-04-06 | 2016-01-13 | Adamas Pharmaceuticals, Inc. | Combination of memantine and donepezil for treatment of CNS disorders |
| US8741343B2 (en) | 2009-12-02 | 2014-06-03 | Adamas Pharmaceuticals, Inc. | Method of administering amantadine prior to a sleep period |
| WO2014204933A1 (en) | 2013-06-17 | 2014-12-24 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54143526A (en) * | 1978-02-22 | 1979-11-08 | Du Pont | Antiidepressant agent composition |
-
1981
- 1981-06-30 JP JP10166581A patent/JPS584718A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54143526A (en) * | 1978-02-22 | 1979-11-08 | Du Pont | Antiidepressant agent composition |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9382640B2 (en) | 2011-12-12 | 2016-07-05 | Shin-Etsu Quartz Products Co., Ltd. | Single crystal silicon pulling silica container and manufacturing method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS584718A (ja) | 1983-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20180008593A1 (en) | Dosage form containing oxycodone and naloxone | |
| WO2008005345A2 (en) | Compositions of 5-ht3 antagonists and dopamine d2 antagonists for treatment of dopamine-associated chronic conditions | |
| JP6137833B2 (ja) | 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用 | |
| Aronow et al. | Childhood poisoning: an unfortunate consequence of methadone availability | |
| JP6228212B2 (ja) | 記憶能力を改善するための向知性組成物 | |
| Zhang et al. | Postoperative anticholinergic poisoning: concealed complications of a commonly used medication | |
| JP2015522077A (ja) | ラキニモドおよびファムプリジンの組合せによる多発性硬化症の治療 | |
| JPH09323927A (ja) | 慢性閉塞性動脈硬化症の治療のためのカルニチン誘導体含有薬剤 | |
| KR20170120708A (ko) | 탈수초를 갖는 환자에서 ４-아미노피리딘을 사용한 지속적 치료 | |
| JP4276779B2 (ja) | 注意欠損／活動亢進症の治療のためのアルカノイルカルニチン誘導体の使用 | |
| JPH022861B2 (ru) | ||
| MX2014003997A (es) | Metodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas. | |
| CA3134145A1 (en) | Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine | |
| JP2022554231A (ja) | 過敏性腸症候群の予防又は治療のための医薬的組み合わせ | |
| Oliveto et al. | D-cycloserine--naloxone interactions in opioid-dependent humans under a novel-response naloxone discrimination procedure. | |
| Barbeau | Levodopa and amyotrophic lateral sclerosis | |
| JPH08119858A (ja) | 自閉症治療剤 | |
| Bewley | Opioid analgesics and narcotic antagonists | |
| Saint-Hyacinthe | T/CMIDAZOLAM INJECTION USP | |
| Pauling | Compound-65 |